Pharmacogenetics

Abstract

Pharmacogenetics (PGt) is the study of the influence of individual variations in deoxyribonucleic acid sequence on drug response. Drug response includes drug disposition (pharmacokinetics) and drug effect (pharmacodynamics). PGt is applicable to activities such as drug discovery, drug development and clinical practise. Currently, there are more than 200 drugs whose labelling includes pharmacogenetic information. ‘Test required’ examples: Cetuximab, Trastuzumab, Maraviroc, Abacavir, Dasatinib, Glivec, Tasigna, Gefitinib and Herceptin; ‘Test recommended’ examples: Carbamazepine, warfarin, azathioprine, etc. In the coming years, evaluation by regulatory authorities of new medicines may involve increasingly PGt components in pre‐ and post‐approval development, and may therefore depend on reliable PGt information. PGt is a rapidly and continuously evolving field; therefore, PGt studies should reflect on the ‘principles’ or necessary qualities of developing well‐controlled, rigorous and reproducible sample handling and testing procedures.

Key Concepts:

  • Pharmacogenetics define populations that can have most benefit from a drug.

  • Pharmacogenetics improve drug development.

  • Pharmacogenetics predict disease course (to justify more intense or prolonged treatments) (diagnostics and prognostics).

  • Pharmacogenetics can be used to monitor the effects of the therapy (pharmacodynamics).

  • Genomic biomarkers predict clinical outcomes (surrogate endpoints).

  • Pharmacogenetics can be useful to identify new biological pathways involved in drug metabolism and therefore new treatment opportunities.

  • Pharmacogenetics is applicable to activities such as drug discovery, drug development and clinical practise.

  • Pharmacogenetics is applicable also in drug disposition (PK) and drug effect (PD).

  • Pharmacogenetics is necessary to define individual dose adaptation of chemotherapeutics and in general for personalised medicine.

  • Pharmacogenetics is crucial in genomic biomarkers identification.

Keywords: pharmacogenetics; cytochrome P450 systems; genomic biomarker; succinylcholine; mivacurium; polymorphic isozymes; thiopurinemethyltransferase

References

Barber MJ, Mangravite LM, Hyde CL et al. (2010) Genome‐wide association of lipid‐lowering response to statins in combined study populations. PLoS One 5(3): e9763.

Billecke S, Draganov D, Counsell R et al. (2000) Human serum paraoxonase (PON1) isozyme Q and R hydrolyze lactones and cyclic carbonate esters. Drug Metabolism and Disposition: The Biological Fate of Chemicals 28: 1335–1342.

Dong XW, Zheng Q, Zhu MM, Tong JL and Ran ZH (2010) Thiopurine S‐methyltransferase polymorphisms and thiopurine toxicity in treatment of inflammatory bowel disease. World Journal of Gastroenterology 16(25): 3187–3195.

Hamburg MA and Collins FS (2010) The path to personalized medicine. New England Journal of Medicine 363: 301–304.

Kalow W (1987) Genetic variation in the human hepatic cytochrome P‐450 system. European Journal of Clinical Pharmacology 31: 633–641.

Kalow W and Genest K (1957) A method for the detection of atypical forms of human serum cholinesterase. Determination of dibucaine numbers. Canadian Journal of Biochemistry and Physiology 35: 339–346.

Li B, Stribley A, Ticu A et al. (2000) Abundant tissue butyrylcholinesterase and its possible function in the acetylcholinesterase knockout mouse. Journal of Neurochemistry 75: 1320–1331.

Novelli G (2010) Personalized genomic medicine. International Journal of Emergency Medicine 5(suppl. 1): S81–90.

Weber WW (1997) Pharmacogenetics. Oxford: Oxford University Press.

Weinshilboum RM and Sladek SL (1980) Mercaptopurine pharmacogenetics: monogenetic inheritance of erythrocyte thiopurine methyltransferase activity. American Journal of Human Genetics 32: 651–662.

Further Reading

Dhand R (ed.) (2000) Functional genomics. Nature Insight 405(6788): 20.

Kalow W (ed.) (1992) Pharmacogenetics of Drug Metabolism. New York: Pergamon Press.

Vesell ES (ed.) (2000) Pharmacogenetics and pharmacogenomics. Recent conceptual and technical advances. Pharmacology 61: 113–228.

Contact Editor close
Submit a note to the editor about this article by filling in the form below.

* Required Field

How to Cite close
Novelli, Giuseppe, and Biancolella, Michela(Jun 2011) Pharmacogenetics. In: eLS. John Wiley & Sons Ltd, Chichester. http://www.els.net [doi: 10.1002/9780470015902.a0002012.pub2]